4SC AG
15
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.7%
1 terminated/withdrawn out of 15 trials
92.9%
+6.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Pre-operative Immunotherapy in Stage II-III Urothelial Cancer
Role: collaborator
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Role: lead
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
Role: lead
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Role: lead
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Role: lead
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
Role: lead
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
Role: collaborator
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies
Role: lead
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
Role: lead
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
Role: lead
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
Role: lead
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
Role: lead
SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Role: lead
SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
Role: lead
Single Dose Study With 4SC-203 in Healthy Volunteers
Role: lead
All 15 trials loaded